Franklin Lakes, N.J.-based BD’s latest milestone comes less than six months after the company surpassed 1 million orders for vaccine delivery devices.
The order total encompasses commitments to governments all over the globe, including the U.S., Australia, Brazil, Canada, France, Germany, India, the Philippines, Saudi Arabia, South Africa, Spain and the UK, among others.
In total, BD is supporting pandemic orders for more than 40 countries, non-governmental organizations and other partners, according to a news release. The company has delivered more than 900 million of the ordered injection devices to date, with the remainder to be delivered between now and the end of 2022.
Devices have been shipped to governments or appointed distribution partners, which will then distribute them to healthcare facilities based on each country’s individual distribution and allocation strategy, BD said, with discussions ongoing to ensure the supply of the delivery devices in late 2022 and beyond.
In December, BD announced its plan to invest $1.2 billion over four years to expand and upgrade multiple drug-delivery facilities. The company said at the time that it intended to open the new facility and build upon its six existing sites in Columbus, Nebraska; Cuautitlán, Mexico; Fukushima, Japan; Le Pont-de-Claix, France; Swindon, United Kingdom; and Tatabánya, Hungary.
Last month, the company confirmed its plans to build a $200 million production site for manufacturing COVID-19 vaccine injection devices in Zaragoza, Spain, which it expects to create up to 600 jobs by 2030.
“Expanding vaccination efforts are bringing restored hope and a long-awaited return to normalcy in multiple countries around the world,” BD president of medication delivery solutions Rick Byrd said in the release. “We are committed to continuing to support government partners and non-governmental organizations in these efforts to ensure health care providers on the front lines of this crisis have these much-needed injection devices to protect their patients from COVID-19.”
